|
PureTech Health plc, a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announced presentations showcasing its deupirfenidone (LYT-100) program at the upcoming American Thoracic Society (ATS) International Conference, taking place in Orlando, Florida, from May 15-20, 2026.
Deupirfenidone is an investigational therapy being advanced by PureTech’s Founded Entity, Celea Therapeutics (Celea), as a potential new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF).
Presentations to highlight differentiated approach to advancing deupirfenidone, reinforcing its potential to serve as a new standard of care within the evolving idiopathic pulmonary fibrosis treatment landscape.
“The SURPASS-IPF program reflects a broader shift in how the field is beginning to think about IPF treatment,” said Toby Maher, MD, PhD, Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles, who will present details around the SURPASS-IPF phase 3 trial. “Historically, clinicians and patients have often accepted modest efficacy because therapeutic options were limited. What makes the phase 3 SURPASS-IPF trial particularly compelling is not only the head-to-head superiority design against a standard of care, but also the strength and consistency of the underlying dataset supporting it.
The previously completed phase 2b ELEVATE IPF trial included an active comparator arm (pirfenidone) that provided important clinical context, while the Qureight analyses further demonstrate that the enrolled population was highly representative of a well-characterized real-world IPF population. Collectively, these elements increase confidence as the program advances into Phase 3 and support the broader hypothesis that greater preservation of lung function may be achievable in IPF.”
“A decade after the introduction of first-generation antifibrotics, enhanced efficacy remains one of the most important unmet needs for people living with IPF,” said Camilla Graham, senior vice president of medical affairs at PureTech. “Our ATS presentations collectively reflect Celea’s strategy to challenge longstanding assumptions in IPF drug development — from designing the first industry-sponsored head-to-head superiority trial in IPF against an approved antifibrotic, to leveraging advanced imaging technologies to better characterize disease severity and strengthen confidence in the translatability of our phase 2b findings into phase 3. Together, these presentations reinforce our belief that deupirfenidone has the potential to meaningfully improve upon the efficacy achieved with current standard-of-care therapies.”
Deupirfenidone (LYT-100) is in development as a potential new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF). It is a next-generation antifibrotic and a deuterated form of pirfenidone, one of three FDA-approved therapies for IPF. The uptake of and adherence to approved antifibrotics has historically been limited by a tradeoff between modest efficacy and tolerability, and only ~25% of people with IPF in the US had ever received treatment as of 2019.
Deupirfenidone may overcome these limitations. In the global phase 2b ELEVATE IPF trial, published in The American Journal of Respiratory and Critical Care Medicine (AJRCCM), deupirfenidone demonstrated the potential to stabilize lung function decline over at least 26 weeks as a monotherapy while maintaining a favourable safety and tolerability profile. Initial data from an ongoing open-label extension study suggest this effect may be sustained through at least 52 weeks. These findings support the potential for deupirfenidone to offer a meaningful advance for people living with this progressive and deadly disease. Beyond IPF, deupirfenidone may also address multiple underserved fibrotic conditions, including progressive fibrosing interstitial lung diseases.
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and fatal lung disease characterized by irreversible scarring of lung tissue that leads to a steady decline in lung function. Median survival following diagnosis is estimated to be two to five years, and currently there is no cure.
Celea Therapeutics is dedicated to advancing transformative treatments for people with serious respiratory diseases. Drawn from the Latin word for “sky,” the name reflects the company’s mission to rise above the status quo and deliver therapies that change lives.
|